依维莫司对常染色体显性遗传性多囊肾病患者多囊肝体积的影响。 - Suppr

Suppr

超能文献

Effect of everolimus on polycystic liver volume in autosomal dominant polycystic kidney disease.

作者信息

Zschiedrich Stefan, Budde Klemens, Walz Gerd

机构信息

Renal Division, Department of Medicine, University Hospital Freiburg, Hugstetter Strasse 55, 79106, Freiburg, Germany,

出版信息

Clin Exp Nephrol. 2015 Aug;19(4):757-8. doi: 10.1007/s10157-014-1059-x. Epub 2014 Nov 26.

DOI:10.1007/s10157-014-1059-x

PMID:25424440

Abstract

摘要

相似文献

Effect of everolimus on polycystic liver volume in autosomal dominant polycystic kidney disease.

Clin Exp Nephrol. 2015 Aug;19(4):757-8. doi: 10.1007/s10157-014-1059-x. Epub 2014 Nov 26.

Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.

BMC Nephrol. 2012 Apr 4;13:17. doi: 10.1186/1471-2369-13-17.

Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.

J Hepatol. 2013 Jul;59(1):153-9. doi: 10.1016/j.jhep.2013.03.004. Epub 2013 Mar 14.

Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.

Gastroenterology. 2019 Aug;157(2):481-491.e7. doi: 10.1053/j.gastro.2019.04.018. Epub 2019 Apr 22.

Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.

Liver Int. 2015 May;35(5):1607-14. doi: 10.1111/liv.12726. Epub 2014 Dec 1.

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

Gastroenterology. 2009 Nov;137(5):1661-8.e1-2. doi: 10.1053/j.gastro.2009.07.052. Epub 2009 Jul 29.

A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease.

Am J Nephrol. 2018;47(5):352-360. doi: 10.1159/000488807. Epub 2018 May 18.

Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.

Clin J Am Soc Nephrol. 2020 Sep 7;15(9):1267-1278. doi: 10.2215/CJN.13661119. Epub 2020 Aug 25.

Somatostatin, estrogen, and polycystic liver disease.

Gastroenterology. 2013 Aug;145(2):279-82. doi: 10.1053/j.gastro.2013.06.025. Epub 2013 Jun 24.

Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.

Gastroenterology. 2013 Aug;145(2):357-65.e1-2. doi: 10.1053/j.gastro.2013.04.055. Epub 2013 May 7.

引用本文的文献

Novel Potential Therapeutic Targets in Autosomal Dominant Polycystic Kidney Disease from the Perspective of Cell Polarity and Fibrosis.

Biomol Ther (Seoul). 2024 May 1;32(3):291-300. doi: 10.4062/biomolther.2023.207. Epub 2024 Apr 9.

本文引用的文献

Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.

J Hepatol. 2013 Jul;59(1):153-9. doi: 10.1016/j.jhep.2013.03.004. Epub 2013 Mar 14.

The long-term outcome of patients with polycystic liver disease treated with lanreotide.

Aliment Pharmacol Ther. 2012 Jan;35(2):266-74. doi: 10.1111/j.1365-2036.2011.04923.x. Epub 2011 Nov 24.

Everolimus in patients with autosomal dominant polycystic kidney disease.

N Engl J Med. 2010 Aug 26;363(9):830-40. doi: 10.1056/NEJMoa1003491. Epub 2010 Jun 26.

Sirolimus reduces polycystic liver volume in ADPKD patients.

J Am Soc Nephrol. 2008 Mar;19(3):631-8. doi: 10.1681/ASN.2007050626. Epub 2008 Jan 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验